These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 8450215

  • 1. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N, Jaffe CL.
    J Immunol; 1993 Mar 15; 150(6):2322-31. PubMed ID: 8450215
    [Abstract] [Full Text] [Related]

  • 2. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis.
    Jaffe CL, Rachamim N, Sarfstein R.
    J Immunol; 1990 Jan 15; 144(2):699-706. PubMed ID: 2295807
    [Abstract] [Full Text] [Related]

  • 3. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK, Titus RG.
    Am J Trop Med Hyg; 2007 Mar 15; 76(3):579-84. PubMed ID: 17360887
    [Abstract] [Full Text] [Related]

  • 4. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M, Bhattacharyya A, Duttagupta S.
    Med Sci Monit; 2002 Apr 15; 8(4):BR117-22. PubMed ID: 11951057
    [Abstract] [Full Text] [Related]

  • 5. Isolation of protective T cells from BALB/cJ mice chronically infected with Leishmania donovani.
    Holaday B, Sadick MD, Pearson RD.
    J Immunol; 1988 Sep 15; 141(6):2132-7. PubMed ID: 3262649
    [Abstract] [Full Text] [Related]

  • 6. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
    Ali N, Afrin F.
    J Parasitol; 1997 Feb 15; 83(1):70-5. PubMed ID: 9057699
    [Abstract] [Full Text] [Related]

  • 7. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK, Naskar K, De T.
    Eur J Immunol; 2009 Aug 15; 39(8):2146-60. PubMed ID: 19593771
    [Abstract] [Full Text] [Related]

  • 8. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 15; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 9. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
    Sharma SK, Dube A, Nadeem A, Khan S, Saleem I, Garg R, Mohammad O.
    Vaccine; 2006 Mar 10; 24(11):1800-10. PubMed ID: 16310900
    [Abstract] [Full Text] [Related]

  • 10. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease.
    Gicheru MM, Olobo JO, Anjili CO.
    Exp Parasitol; 1997 Feb 10; 85(2):109-16. PubMed ID: 9030661
    [Abstract] [Full Text] [Related]

  • 11. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

  • 12. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, Alawa CB, Alsaadi M, Mullen AB, Carter KC.
    Vaccine; 2012 Feb 08; 30(7):1357-63. PubMed ID: 22210224
    [Abstract] [Full Text] [Related]

  • 13. An experimental vaccine providing heterologous protection for Leishmania species in murine model.
    Bebars MA, el Serougi AO, Makled KM, Mikhael EM, Abou Gamra MM, el Sherbiny M, Mohareb AW, Mohammed EA.
    J Egypt Soc Parasitol; 2000 Apr 08; 30(1):137-56. PubMed ID: 10786026
    [Abstract] [Full Text] [Related]

  • 14. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S.
    Scand J Immunol; 2008 Nov 08; 68(5):492-501. PubMed ID: 18803606
    [Abstract] [Full Text] [Related]

  • 15. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P, Pandya J, Mehta J, Sukumaran B, Madhubala R.
    FEMS Immunol Med Microbiol; 2004 Oct 01; 42(2):241-8. PubMed ID: 15364110
    [Abstract] [Full Text] [Related]

  • 16. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
    Nagill R, Mahajan R, Sharma M, Kaur S.
    Parasitol Int; 2009 Dec 01; 58(4):359-66. PubMed ID: 19638322
    [Abstract] [Full Text] [Related]

  • 17. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
    Bhaumik S, Basu R, Sen S, Naskar K, Roy S.
    Vaccine; 2009 Feb 25; 27(9):1306-16. PubMed ID: 19162111
    [Abstract] [Full Text] [Related]

  • 18. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G.
    Vaccine; 2005 Apr 22; 23(22):2825-40. PubMed ID: 15780731
    [Abstract] [Full Text] [Related]

  • 19. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
    Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A.
    J Immunol; 2011 Dec 15; 187(12):6417-27. PubMed ID: 22079980
    [Abstract] [Full Text] [Related]

  • 20. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS, Bayih AG, Gedamu L.
    Exp Parasitol; 2012 Jul 15; 131(3):317-24. PubMed ID: 22580023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.